Dementia With Diabetes Market Expected to Experience Major Growth by 2032, According to DelveInsight | Novo Nordisk, Pfizer, EIP Pharma, Sun Pharma, Allyx Therapeutics, Bioxcel Therapeutics

March 18 08:58 2025
Dementia With Diabetes Market Expected to Experience Major Growth by 2032, According to DelveInsight | Novo Nordisk, Pfizer, EIP Pharma, Sun Pharma, Allyx Therapeutics, Bioxcel Therapeutics
The Key Dementia With Diabetes Companies in the market include – Novo Nordisk, Pfizer, EIP Pharma, Sun Pharma, Allyx Therapeutics, Bioxcel Therapeutics, and others.

 

DelveInsight’s “Dementia With Diabetes Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Dementia With Diabetes, historical and forecasted epidemiology as well as the Dementia With Diabetes market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Dementia With Diabetes market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dementia With Diabetes Market Forecast

 

Some of the key facts of the Dementia With Diabetes Market Report:

  • The Dementia With Diabetes market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • The most prevalent kind of dementia, according to the Centers for Disease Control and Prevention (2022), is Alzheimer’s disease. As of right now, estimates place the number of Americans with Alzheimer’s disease and related dementias at 5.8 million, including 5.6 million persons 65 years of age and older and roughly 200,000 people under 65 with younger-onset Alzheimer’s

  • Goodman et al. (2023) reported that Alzheimer’s (43.5%) was the most prevalent category, with vascular (14.5%), Lewy body (5.4%), frontotemporal (1.0%), and alcohol-induced (0.7%) following closely behind. In the US, the prevalence of other diagnosed forms of dementia was 0.2%

  • Over 900,000 people in the UK are thought to have dementia, according to Dementia UK (2023).

  • Reinke et al. (2022) reported that a cohort study using German health claims data revealed that the risk of dementia fell by 26% after a year of type 2 diabetes diagnosis, reaching a lowest at 4.75 years, and then increased until the conclusion of the follow-up.

  • Key Dementia With Diabetes Companies: Novo Nordisk, Pfizer, EIP Pharma, Sun Pharma, Allyx Therapeutics, Bioxcel Therapeutics, and others

  • Key Dementia With Diabetes Therapies: Thiazolidinediones, Meglitinides, GLP-1 receptor agonists, DPP-4 inhibitors, and others

  • The Dementia With Diabetes market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dementia With Diabetes pipeline products will significantly revolutionize the Dementia With Diabetes market dynamics.

 

Dementia With Diabetes Overview

Dementia with diabetes” refers to the condition where individuals with diabetes develop dementia, a general term for a decline in cognitive ability severe enough to interfere with daily life. Diabetes can increase the risk of developing various types of dementia, including Alzheimer’s disease and vascular dementia.

 

Get a Free sample for the Dementia With Diabetes Market Report

https://www.delveinsight.com/report-store/dementia-with-diabetes-market-forecast

 

Dementia With Diabetes Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Dementia With Diabetes Epidemiology Segmentation:

The Dementia With Diabetes market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Dementia With Diabetes

  • Prevalent Cases of Dementia With Diabetes by severity

  • Gender-specific Prevalence of Dementia With Diabetes

  • Diagnosed Cases of Episodic and Chronic Dementia With Diabetes

 

Download the report to understand which factors are driving Dementia With Diabetes epidemiology trends @ Dementia With Diabetes Epidemiology Forecast

 

Dementia With Diabetes Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dementia With Diabetes market or expected to get launched during the study period. The analysis covers Dementia With Diabetes market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dementia With Diabetes Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Key Dementia with DiabetesTherapies and Companies:

  • Thiazolidinediones: Novo Nordisk

  • Meglitinides: Pfizer

  • GLP-1 receptor agonists: EIP Pharma

  • DPP-4 inhibitors: Sun Pharma

 

Discover more about therapies set to grab major Dementia With Diabetes market share @ Dementia With Diabetes Treatment Market

 

Dementia With Diabetes Market Unmet Needs

  • Lack of epidemiological data

  • Early detection and diagnosis

  • Scarcity of approved therapies and challenges in treatment

  • Integrated Care Approach

  • Impact on quality of life

 

Scope of the Dementia With Diabetes Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Dementia With Diabetes Companies: Novo Nordisk, Pfizer, EIP Pharma, Sun Pharma, Allyx Therapeutics, Bioxcel Therapeutics, and others

  • Key Dementia With Diabetes Therapies: Thiazolidinediones, Meglitinides, GLP-1 receptor agonists, DPP-4 inhibitors, and others

  • Dementia With Diabetes Therapeutic Assessment: Dementia With Diabetes current marketed and Dementia With Diabetes emerging therapies

  • Dementia With Diabetes Market Dynamics: Dementia With Diabetes market drivers and Dementia With Diabetes market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Dementia With Diabetes Unmet Needs, KOL’s views, Analyst’s views, Dementia With Diabetes Market Access and Reimbursement

 

To know more about Dementia With Diabetes companies working in the treatment market, visit @ Dementia With Diabetes Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Dementia With Diabetes Market Report Introduction

2. Executive Summary for Dementia With Diabetes

3. SWOT analysis of Dementia With Diabetes

4. Dementia With Diabetes Patient Share (%) Overview at a Glance

5. Dementia With Diabetes Market Overview at a Glance

6. Dementia With Diabetes Disease Background and Overview

7. Dementia With Diabetes Epidemiology and Patient Population

8. Country-Specific Patient Population of Dementia With Diabetes

9. Dementia With Diabetes Current Treatment and Medical Practices

10. Dementia With Diabetes Unmet Needs

11. Dementia With Diabetes Emerging Therapies

12. Dementia With Diabetes Market Outlook

13. Country-Wise Dementia With Diabetes Market Analysis (2019–2032)

14. Dementia With Diabetes Market Access and Reimbursement of Therapies

15. Dementia With Diabetes Market Drivers

16. Dementia With Diabetes Market Barriers

17. Dementia With Diabetes Appendix

18. Dementia With Diabetes Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/